---
title: "Down Round, Definition | MedTech Terms"
description: "Financing at a lower per-share price than the previous round. Plain-English Investment &amp; Finance definition for MedTech teams, with examples and related terms."
lang: en
json-ld: |
  {
    "@context": "https://schema.org",
    "@graph": [
      {
        "@type": "DefinedTerm",
        "@id": "https://medtechterms.com/terms/down-round#term",
        "name": "Down Round",
        "description": "A down round prices new shares below the prior round's price per share, typically triggering anti-dilution adjustments and signaling that the company has missed expectations.",
        "url": "https://medtechterms.com/terms/down-round",
        "termCode": "down-round",
        "inDefinedTermSet": {
          "@type": "DefinedTermSet",
          "name": "MedTech Terms",
          "url": "https://medtechterms.com/terms"
        }
      },
      {
        "@type": "Article",
        "@id": "https://medtechterms.com/terms/down-round#article",
        "headline": "Down Round",
        "description": "Financing at a lower per-share price than the previous round.",
        "url": "https://medtechterms.com/terms/down-round",
        "mainEntityOfPage": {
          "@type": "WebPage",
          "@id": "https://medtechterms.com/terms/down-round"
        },
        "about": {
          "@id": "https://medtechterms.com/terms/down-round#term"
        },
        "articleSection": "Investment & Finance",
        "inLanguage": "en",
        "keywords": "Down Round, Investment & Finance, medical device, MedTech",
        "author": {
          "@type": "Person",
          "name": "Christian Espinosa",
          "jobTitle": "Founder, Blue Goat Cyber",
          "url": "https://bluegoatcyber.com"
        },
        "publisher": {
          "@type": "Organization",
          "name": "MedTech Terms",
          "url": "https://medtechterms.com"
        },
        "isPartOf": {
          "@type": "WebSite",
          "name": "MedTech Terms",
          "url": "https://medtechterms.com"
        },
        "datePublished": "2026-05-05",
        "dateModified": "2026-05-05",
        "citation": [
          {
            "@type": "CreativeWork",
            "name": "Cooley GO: down rounds",
            "url": "https://www.cooleygo.com/",
            "publisher": {
              "@type": "Organization",
              "name": "Cooley GO"
            }
          },
          {
            "@type": "CreativeWork",
            "name": "NVCA Model Documents",
            "url": "https://nvca.org/model-legal-documents/",
            "publisher": {
              "@type": "Organization",
              "name": "NVCA"
            }
          },
          {
            "@type": "CreativeWork",
            "name": "Silicon Valley Bank - Healthcare Reports",
            "url": "https://www.svb.com/trends-insights/",
            "publisher": {
              "@type": "Organization",
              "name": "SVB"
            }
          }
        ],
        "mentions": [
          {
            "@type": "DefinedTerm",
            "@id": "https://medtechterms.com/terms/anti-dilution#term",
            "name": "Anti-Dilution Protection",
            "url": "https://medtechterms.com/terms/anti-dilution"
          }
        ]
      },
      {
        "@type": "BreadcrumbList",
        "itemListElement": [
          {
            "@type": "ListItem",
            "position": 1,
            "name": "Home",
            "item": "https://medtechterms.com/"
          },
          {
            "@type": "ListItem",
            "position": 2,
            "name": "Terms",
            "item": "https://medtechterms.com/terms"
          },
          {
            "@type": "ListItem",
            "position": 3,
            "name": "Investment & Finance",
            "item": "https://medtechterms.com/terms?cat=Investment%20%26%20Finance"
          },
          {
            "@type": "ListItem",
            "position": 4,
            "name": "Down Round",
            "item": "https://medtechterms.com/terms/down-round"
          }
        ]
      },
      {
        "@type": "FAQPage",
        "@id": "https://medtechterms.com/terms/down-round#faq",
        "mainEntity": [
          {
            "@type": "Question",
            "name": "How do regulatory failures contribute to a down round?",
            "acceptedAnswer": {
              "@type": "Answer",
              "text": "Regulatory failures, such as a product not receiving FDA clearance or approval following a pivotal trial, can significantly diminish a company's valuation, leading to a down round. These failures indicate that the product may not meet safety and efficacy requirements, impacting its market viability."
            }
          },
          {
            "@type": "Question",
            "name": "What quality system deficiencies might precede a down round?",
            "acceptedAnswer": {
              "@type": "Answer",
              "text": "Quality system deficiencies, including inadequate design controls (21 CFR 820.30) leading to product defects or poor risk management (ISO 14971:2019), can result in product recalls or safety signals. These events often reduce investor confidence and can necessitate a down round to secure further funding."
            }
          },
          {
            "@type": "Question",
            "name": "Can cybersecurity issues lead to a down round?",
            "acceptedAnswer": {
              "@type": "Answer",
              "text": "Yes, significant cybersecurity breaches or vulnerabilities that lead to product recalls or regulatory actions (e.g., under FDA's cybersecurity guidance) can damage a MedTech company's reputation and financial standing, potentially triggering a down round."
            }
          },
          {
            "@type": "Question",
            "name": "Are there regulatory reporting requirements associated with events that cause a down round?",
            "acceptedAnswer": {
              "@type": "Answer",
              "text": "Events like failed clinical trials, product recalls, or adverse events that could precipitate a down round often have specific regulatory reporting requirements. For instance, adverse event reporting falls under 21 CFR Part 803 for medical devices."
            }
          }
        ]
      }
    ]
  }
---

[

MedTech Terms

The authoritative reference



](/)

Browse

Learn

[Latest](/latest)

About

1.  [Home](/)
2.  /
3.  [Terms](/terms)
4.  /
5.  [Investment & Finance](/terms?cat=Investment%20%26%20Finance)
6.  /
7.  Down Round

[All terms](/terms)

Investment & Finance [Startup Lifecycle](/ecosystems/startup-lifecycle)

# Down Round

Financing at a lower per-share price than the previous round.

Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 5, 2026 

## Definition

A down round prices new shares below the prior round's price per share, typically triggering anti- [dilution](/terms/dilution) adjustments and signaling that the company has missed expectations. 

What the regulation says

While "down rounds" are a financial concept, their underlying causes, such as failed pivotal trials or significant post-market safety signals, directly relate to regulatory compliance and quality system effectiveness. Regulatory bodies like the FDA expect companies to maintain robust  [design controls](/terms/design-controls) as per 21 CFR 820.30 and conduct thorough clinical investigations, as outlined in 21 CFR Part 812, to minimize such failures. Poor cybersecurity leading to product recalls could also trigger a down round, highlighting the importance of cybersecurity risk management per FDA guidance. 

## What this means in practice

MedTech down rounds frequently follow failed pivotal trials, FDA non-clearances, or post-market safety signals. A well-structured 'pay-to-play' can keep insiders engaged and prevent worst-case  [dilution](/terms/dilution) math. 

## Examples

-   A MedTech startup fails to secure FDA 510(k) clearance for its new diagnostic device after unexpected clinical trial results, leading to a down round for its next funding round.
-   A company faces a significant product recall due to a manufacturing defect traced back to poor quality controls, resulting in a devaluation and a subsequent down round.
-   A post-market surveillance report reveals a previously unknown safety issue with an implanted device, requiring extensive remediation efforts and causing investors to re-price the company in a down round.

Common pitfalls

-   • Failing to understand that a down round often signals underlying issues in regulatory strategy, quality management, or product development lifecycle. 
-   • Assuming that financial remedies like "pay-to-play" provisions negate the need for addressing the root causes related to regulatory non-compliance or product quality. 
-   • Neglecting to perform a thorough post-market surveillance and corrective and preventive action (CAPA) process after a significant product issue, which could lead to a down round. 
-   • Underestimating the impact of regulatory non-compliance fines or market withdrawals, which can be precursors to a down round, on investor confidence. 
-   • Not recognizing that repeated down rounds can indicate systemic problems in a company's ability to meet regulatory milestones or product performance expectations. 

## Frequently asked questions

How do regulatory failures contribute to a down round? 

Regulatory failures, such as a product not receiving FDA clearance or approval following a  [pivotal trial](/terms/pivotal-trial), can significantly diminish a company's valuation, leading to a down round. These failures indicate that the product may not meet safety and efficacy requirements, impacting its market viability. 

What quality system deficiencies might precede a down round? 

Can cybersecurity issues lead to a down round? 

Are there regulatory reporting requirements associated with events that cause a down round? 

## Related terms

Grouped by theme 

### Editor's picks

· Hand-selected related concepts 

[

Investment & Finance

Anti-Dilution Protection

Adjustment that protects investors if the company raises a future round at a lower price.





](/terms/anti-dilution)

### More in Investment & Finance

· Same category 

[

Investment & Finance

409A Valuation

An independent fair-market-value appraisal of common stock used to set tax-compliant strike prices for employee stock options.





](/terms/409a-valuation)[

Investment & Finance

Bridge Round

Interim financing between priced rounds, usually convertible.





](/terms/bridge-round)[

Investment & Finance

Burn Rate

Rate at which a company spends cash, typically expressed monthly.





](/terms/burn-rate)[

Investment & Finance

Burn Rate and Runway

Monthly net cash consumption (burn) and months of cash remaining (runway).





](/terms/burn-runway)

Cited by

Where this term appears across MedTech Terms.

Ecosystems (1)

-   [Startup Lifecycle](/ecosystems/startup-lifecycle)

## Primary references

3 sources 

Link health:  3 verified · last checked 2026-06-20 

Cooley GO· 1 NVCA· 1 SVB· 1 

1.  [1 
    
    Cooley GO: down rounds
    
    Verified 
    
    Cooley GO · cooleygo.com 
    
    
    
    ](https://www.cooleygo.com/)
2.  [2 
    
    NVCA Model Documents
    
    Verified 
    
    NVCA · nvca.org 
    
    
    
    ](https://nvca.org/model-legal-documents/)
3.  [3 
    
    Silicon Valley Bank - Healthcare Reports
    
    Verified 
    
    SVB · svb.com 
    
    
    
    ](https://www.svb.com/trends-insights/)

Inline markers like \[1\]  jump to the matching reference above.

Sponsor note

### Diligencing a MedTech cybersecurity posture?

Blue Goat Cyber supports investors and acquirers with cybersecurity diligence on connected MedTech assets.

[Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session)

-   No obligation
-   Expert-led from minute one
-   NDA available on request

MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor.

On this term

Category

Investment & Finance

Sources

3

Updated

5/5/2026

[Compare with another term](/compare?a=down-round)

Learn in 60 seconds

Card Lesson Quiz

Financing at a lower per-share price than the previous round.

-   · MedTech down rounds frequently follow failed pivotal trials, FDA non-clearances, or post-market safety signals. 
-   · A well-structured 'pay-to-play' can keep insiders engaged and prevent worst-case dilution math. 

Remember this

Watch out: Failing to understand that a down round often signals underlying issues in regulatory strategy, quality management, or product development lifecycle.

Related terms

-   [Anti-Dilution Protection ](/terms/anti-dilution)

You may also need

Auto-suggested from Investment & Finance and shared keywords.

-   [409A Valuation ](/terms/409a-valuation)
-   [Pre-Money Valuation ](/terms/pre-money-valuation)
-   [Capitalization Table(Cap Table) ](/terms/cap-table)
-   [Convertible Note ](/terms/convertible-note)
-   [Drag-Along and Tag-Along Rights ](/terms/drag-tag-along)
-   [Simple Agreement for Future Equity(SAFE) ](/terms/safe-note)

[All Investment & Finance terms](/terms?cat=Investment%20%26%20Finance)

MedTech Terms 

An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices.

Browse

-   [All terms](/terms)
-   [A–Z index](/a-z)
-   [Categories](/categories)
-   [Ecosystems](/ecosystems)
-   [Learning paths](/paths)
-   [Compare terms](/compare)
-   [Quiz](/quiz)

Resources

-   [FDA Medical Devices](https://www.fda.gov/medical-devices)
-   [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj)
-   [IMDRF](https://www.imdrf.org/)
-   [Methodology](/methodology)
-   [Changelog](/changelog)
-   [Editor: Christian Espinosa](/authors/christian-espinosa)
-   [About this site](/about)

© 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)